Systems approaches to studying the immune response in tuberculosis

Current Opinion in Immunology

Volumn 25, Issue 5, 2013, Pages 579-587

  Berry, Matthew Paul Reddoch ^a,b   Blankley, Simon ^a   Graham, Christine Marian ^a   Bloom, Chloe I ^a   O'Garra, Anne ^a,c  

^a NATIONAL INSTITUTE FOR MEDICAL RESEARCH   (United Kingdom)

^b ST MARY S HOSPITAL   (United Kingdom)

^c IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BETA INTERFERON; GAMMA INTERFERON; INTERFERON;

ADAPTIVE IMMUNITY; B LYMPHOCYTE; BACTERIAL STRAIN; CELL POPULATION; COHORT ANALYSIS; DNA SEQUENCE; FLOW CYTOMETRY; HUMAN; IMMUNOPATHOGENESIS; IN VITRO STUDY; INNATE IMMUNITY; LUNG SARCOIDOSIS; LUNG TUBERCULOSIS; METABOLOMICS; MONOCYTE; MYCOBACTERIUM BOVIS; MYCOBACTERIUM TUBERCULOSIS; NEUTROPHIL; NONHUMAN; PROTEOMICS; REVIEW; SIGNAL TRANSDUCTION; SYSTEMS BIOLOGY; T LYMPHOCYTE; ANIMAL; HOST PATHOGEN INTERACTION; IMMUNOLOGY; ISOLATION AND PURIFICATION; LYMPHOCYTE; METHODOLOGY; MICROBIOLOGY; TUBERCULOSIS; PROCEDURES;

ANIMALS; HOST-PATHOGEN INTERACTIONS; HUMANS; INTERFERON TYPE I; LYMPHOCYTES; MYCOBACTERIUM TUBERCULOSIS; SYSTEMS BIOLOGY; TUBERCULOSIS;

EID: 84898018651     PISSN: 09527915     EISSN: 18790372     Source Type: Journal    
DOI: 10.1016/j.coi.2013.08.003     Document Type: Review

References (58)

1. 1 Floyd, K., Dias, H.M., Falzon, D., Fitzpatrick, C., Glaziou, P., Hiatt, T., Lienhardt, C., Nguyen, L., Sismanidis, C., Timimi, H., et al. Global Tuberculosis Report 2012., 2012, World Health Organization, Geneva, Switzerland.
2. 2•• O'Garra, A., Redford, P.S., McNab, F.W., Bloom, C.I., Wilkinson, R.J., Berry, M.P., The immune response in tuberculosis. Annu Rev Immunol 31 (2013), 475–527 This review provides an overview of our current understanding of the immune response to tuberculosis, in the context of the challenges created by its complex epidemiology and varied clinical presentations.
3. 3 Barry, C.E. 3rd, Boshoff, H.I., Dartois, V., Dick, T., Ehrt, S., Flynn, J., Schnappinger, D., Wilkinson, R.J., Young, D., The spectrum of latent tuberculosis: rethinking the biology and intervention strategies. Nat Rev Microbiol 7 (2009), 845–855.
4. 4 Oni, T., Burke, R., Tsekela, R., Bangani, N., Seldon, R., Gideon, H.P., Wood, K., Wilkinson, K.A., Ottenhoff, T.H., Wilkinson, R.J., High prevalence of subclinical tuberculosis in HIV-1-infected persons without advanced immunodeficiency: implications for TB scrseening. Thorax 66 (2011), 669–673.
5. 5 Ottenhoff, T.H., Overcoming the global crisis: “yes, we can”, but also for TB…?. Eur J Immunol 39 (2009), 2014–2020.
6. 6•• Tameris, M.D., Hatherill, M., Landry, B.S., Scriba, T.J., Snowden, M.A., Lockhart, S., Shea, J.E., McClain, J.B., Hussey, G.D., Hanekom, W.A., et al. Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial. Lancet, 2013 This paper describes the first human infant efficacy trial of a new TB vaccine candidate since BCG, and represents a landmark step in the quest to develop new vaccines.
7. 7 Pitt, J.M., Blankley, S., McShane, H., O'Garra, A., Vaccination against tuberculosis: How can we better BCG?. Microb Pathog 58 (2013), 2–16.
8. 8 Shapira, S.D., Hacohen, N., Systems biology approaches to dissect mammalian innate immunity. Curr Opin Immunol 23 (2010), 71–77.
9. 9 Cole, S.T., Brosch, R., Parkhill, J., Garnier, T., Churcher, C., Harris, D., Gordon, S.V., Eiglmeier, K., Gas, S., Barry, C.E. 3rd, et al. Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. Nature 393 (1998), 537–544.
10. 10 Mukhopadhyay, S., Nair, S., Ghosh, S., Pathogenesis in tuberculosis: transcriptomic approaches to unraveling virulence mechanisms and finding new drug targets. FEMS Microbiol Rev 36 (2012), 463–485.
11. 11 Comas, I., Gagneux, S., A role for systems epidemiology in tuberculosis research. Trends Microbiol 19 (2011), 492–500.
12. 12 Sandhu, G., Battaglia, F., Ely, B.K., Athanasakis, D., Montoya, R., Valencia, T., Gilman, R.H., Evans, C.A., Friedland, J.S., Fernandez-Reyes, D., et al. Discriminating active from latent tuberculosis in patients presenting to community clinics. PLoS One, 7, 2012, e38080.
13. 13 Agranoff, D., Fernandez-Reyes, D., Papadopoulos, M.C., Rojas, S.A., Herbster, M., Loosemore, A., Tarelli, E., Sheldon, J., Schwenk, A., Pollok, R., et al. Identification of diagnostic markers for tuberculosis by proteomic fingerprinting of serum. Lancet 368 (2006), 1012–1021.
14. 14 De Groote, M.A., Nahid, P., Jarlsberg, L., Johnson, J.L., Weiner, M., Muzanyi, G., Janjic, N., Sterling, D.G., Ochsner, U.A., Elucidating novel serum biomarkers associated with pulmonary tuberculosis treatment. PLoS One, 8, 2013, e61002.
15. 15• Weiner, J. 3rd, Parida, S.K., Maertzdorf, J., Black, G.F., Repsilber, D., Telaar, A., Mohney, R.P., Arndt-Sullivan, C., Ganoza, C.A., Fae, K.C., et al. Biomarkers of inflammation, immunosuppression and stress with active disease are revealed by metabolomic profiling of tuberculosis patients. PLoS One, 7, 2012, e40221 This study provides proof of principle for metabolomic profiling and highlights a role for tryptophan metabolism in the immune response to TB, consistent with earlier reports in animal models and from gene expression studies.
16. 16 Suzuki, Y., Suda, T., Asada, K., Miwa, S., Suzuki, M., Fujie, M., Furuhashi, K., Nakamura, Y., Inui, N., Shirai, T., et al. Serum indoleamine 2,3-dioxygenase activity predicts prognosis of pulmonary tuberculosis. Clin Vaccine Immunol 19 (2012), 436–442.
17. 17 Zelante, T., Fallarino, F., Bistoni, F., Puccetti, P., Romani, L., Indoleamine 2,3-dioxygenase in infection: the paradox of an evasive strategy that benefits the host. Microbes Infect 11 (2009), 133–141.
18. 18 Simon, R., Radmacher, M.D., Dobbin, K., McShane, L.M., Pitfalls in the use of DNA microarray data for diagnostic and prognostic classification. J Natl Cancer Inst 95 (2003), 14–18.
19. 19 Chaussabel, D., Pascual, V., Banchereau, J., Assessing the human immune system through blood transcriptomics. BMC Biol, 8, 2010, 84.
20. 20 Reis-Filho, J.S., Pusztai, L., Gene expression profiling in breast cancer: classification, prognostication, and prediction. Lancet 378 (2012), 1812–1823.
21. 21 Pascual, V., Chaussabel, D., Banchereau, J., A genomic approach to human autoimmune diseases. Annu Rev Immunol 28 (2010), 535–571.
22. 22 Jacobsen, M., Repsilber, D., Gutschmidt, A., Neher, A., Feldmann, K., Mollenkopf, H.J., Ziegler, A., Kaufmann, S.H., Candidate biomarkers for discrimination between infection and disease caused by Mycobacterium tuberculosis. J Mol Med 85 (2007), 613–621.
23. 23 Mistry, R., Cliff, J.M., Clayton, C.L., Beyers, N., Mohamed, Y.S., Wilson, P.A., Dockrell, H.M., Wallace, D.M., van Helden, P.D., Duncan, K., et al. Gene-expression patterns in whole blood identify subjects at risk for recurrent tuberculosis. J Infect Dis 195 (2007), 357–365.
24. 24 Kim, D.K., Park, G.M., Hwang, Y.I., Kim, H.J., Han, S.K., Shim, Y.S., Yim, J.J., Microarray analysis of gene expression associated with extrapulmonary dissemination of tuberculosis. Respirology 11 (2006), 557–565.
25. 25•• Berry, M.P., Graham, C.M., McNab, F.W., Xu, Z., Bloch, S.A., Oni, T., Wilkinson, K.A., Banchereau, R., Skinner, J., Wilkinson, R.J., et al. An interferon-inducible neutrophil-driven blood transcriptional signature in human tuberculosis. Nature 466 (2010), 973–977 This manuscript was the first to describe a blood transcriptional profile of active tuberculosis that was absent in latent disease, demonstrating an interferon-inducible signature of active tuberculosis which correlated with the extent of lung radiographic disease and was diminished upon treatment.
26. 26 Maertzdorf, J., Repsilber, D., Parida, S.K., Stanley, K., Roberts, T., Black, G., Walzl, G., Kaufmann, S.H., Human gene expression profiles of susceptibility and resistance in tuberculosis. Genes Immun 12 (2011), 15–22.
27. 27•• Maertzdorf, J., Ota, M., Repsilber, D., Mollenkopf, H.J., Weiner, J., Hill, P.C., Kaufmann, S.H., Functional correlations of pathogenesis-driven gene expression signatures in tuberculosis. PLoS One, 6, 2011, e26938 This study confirms the reproducibility of the characteristic interferon-inducible blood transcriptional signature of human TB, validating earlier findings despite the use of different microarray platforms, blood collection and processing.
28. 28 Lesho, E., Forestiero, F.J., Hirata, M.H., Hirata, R.D., Cecon, L., Melo, F.F., Paik, S.H., Murata, Y., Ferguson, E.W., Wang, Z., et al. Transcriptional responses of host peripheral blood cells to tuberculosis infection. Tuberculosis (Edinb) 91 (2011), 390–399.
29. 29•• Ottenhoff, T.H., Dass, R.H., Yang, N., Zhang, M.M., Wong, H.E., Sahiratmadja, E., Khor, C.C., Alisjahbana, B., van Crevel, R., Marzuki, S., et al. Genome-wide expression profiling identifies type 1 interferon response pathways in active tuberculosis. PLoS One, 7, 2012, e45839 This study also validates the characteristic interferon-inducible blood transcriptional signature in human TB, but also importantly identifies common interferon-inducible responses in the lungs of infected mice and in infected human macrophages.
30. 30•• Maertzdorf, J., Weiner, J. 3rd, Mollenkopf, H.J., Bauer, T., Prasse, A., Muller-Quernheim, J., Kaufmann, S.H., Common patterns and disease-related signatures in tuberculosis and sarcoidosis. Proc Natl Acad Sci U S A 109 (2012), 7853–7858 This study is the first to perform a direct comparison of blood transcriptional profiles from patients with TB and Sarcoidosis and to identify common and distinct signatures.
31. 31 Remoli, M.E., Giacomini, E., Lutfalla, G., Dondi, E., Orefici, G., Battistini, A., Uze, G., Pellegrini, S., Coccia, E.M., Selective expression of type I IFN genes in human dendritic cells infected with Mycobacterium tuberculosis. J Immunol 169 (2002), 366–374.
32. 32 Chaussabel, D., Semnani, R.T., McDowell, M.A., Sacks, D., Sher, A., Nutman, T.B., Unique gene expression profiles of human macrophages and dendritic cells to phylogenetically distinct parasites. Blood 102 (2003), 672–681.
33. 33 Tailleux, L., Waddell, S.J., Pelizzola, M., Mortellaro, A., Withers, M., Tanne, A., Castagnoli, P.R., Gicquel, B., Stoker, N.G., Butcher, P.D., et al. Probing host pathogen cross-talk by transcriptional profiling of both Mycobacterium tuberculosis and infected human dendritic cells and macrophages. PLoS One, 3, 2008, e1403.
34. 34 Wu, K., Dong, D., Fang, H., Levillain, F., Jin, W., Mei, J., Gicquel, B., Du, Y., Wang, K., Gao, Q., et al. An interferon-related signature in the transcriptional core response of human macrophages to Mycobacterium tuberculosis infection. PLoS One, 7, 2012, e38367.
35. 35 Bouchonnet, F., Boechat, N., Bonay, M., Hance, A.J., Alpha/beta interferon impairs the ability of human macrophages to control growth of Mycobacterium bovis BCG. Infect Immun 70 (2002), 3020–3025.
36. 36 Manca, C., Tsenova, L., Freeman, S., Barczak, A.K., Tovey, M., Murray, P.J., Barry, C., Kaplan, G., Hypervirulent M. tuberculosis W/Beijing strains upregulate type I IFNs and increase expression of negative regulators of the Jak-Stat pathway. J Interferon Cytokine Res 25 (2005), 694–701.
37. 37 Stanley, S.A., Johndrow, J.E., Manzanillo, P., Cox, J.S., The Type I IFN response to infection with Mycobacterium tuberculosis requires ESX-1-mediated secretion and contributes to pathogenesis. J Immunol 178 (2007), 3143–3152.
38. 38•• Mayer-Barber, K.D., Andrade, B.B., Barber, D.L., Hieny, S., Feng, C.G., Caspar, P., Oland, S., Gordon, S., Sher, A., Innate and adaptive interferons suppress IL-1alpha and IL-1beta production by distinct pulmonary myeloid subsets during Mycobacterium tuberculosis infection. Immunity 35 (2011), 1023–1034 This study highlights a potentially detrimental role for type I interferons during TB, through suppression of IL-1.
39. 39 Cooper, A.M., Pearl, J.E., Brooks, J.V., Ehlers, S., Orme, I.M., Expression of the nitric oxide synthase 2 gene is not essential for early control of Mycobacterium tuberculosis in the murine lung. Infect Immun 68 (2000), 6879–6882.
40. 40 Kuchtey, J., Fulton, S.A., Reba, S.M., Harding, C.V., Boom, W.H., Interferon-alphabeta mediates partial control of early pulmonary Mycobacterium bovis bacillus Calmette-Guerin infection. Immunology 118 (2006), 39–49.
41. 41•• Teles, R.M., Graeber, T.G., Krutzik, S.R., Montoya, D., Schenk, M., Lee, D.J., Komisopoulou, E., Kelly-Scumpia, K., Chun, R., Iyer, S.S., et al. Type I interferon suppresses type II interferon-triggered human anti-mycobacterial responses. Science 339 (2013), 1448–1453 Through microarray analysis of human tissue, supported by in vitro models and analysis of deposited data, this study suggests that in the mycobacterial disease leprosy, the balance of type I and type II interferons determines protective or susceptible host immune responses.
42. 42• Verhagen, L.M., Zomer, A., Maes, M., Villalba, J.A., Del Nogal, B., Eleveld, M., van Hijum, S.A., de Waard, J.H., Hermans, P.W., A predictive signature gene set for discriminating active from latent tuberculosis in Warao Amerindian children. BMC Genomics, 14, 2013, 74 The first blood transcriptional profiling study in human TB to study children, this shows that signatures defined in adults may not be directly applicable to the paediatric population.
43. 43 Koth, L.L., Solberg, O.D., Peng, J.C., Bhakta, N.R., Nguyen, C.P., Woodruff, P.G., Sarcoidosis blood transcriptome reflects lung inflammation and overlaps with tuberculosis. Am J Respir Crit Care Med 184 (2011), 1153–1163.
44. 44 Dupuy, A., Simon, R.M., Critical review of published microarray studies for cancer outcome and guidelines on statistical analysis and reporting. J Natl Cancer Inst 99 (2007), 147–157.
45. 45 Koh, G.C., Schreiber, M.F., Bautista, R., Maude, R.R., Dunachie, S., Limmathurotsakul, D., Day, N.P., Dougan, G., Peacock, S.J., Host responses to melioidosis and tuberculosis are both dominated by interferon-mediated signaling. PLoS One, 8, 2013, e54961.
46. 46 Pankla, R., Buddhisa, S., Berry, M., Blankenship, D.M., Bancroft, G.J., Banchereau, J., Lertmemongkolchai, G., Chaussabel, D., Genomic transcriptional profiling identifies a candidate blood biomarker signature for the diagnosis of septicemic melioidosis. Genome Biol, 10, 2009, R127.
47. 47 Lu, C., Wu, J., Wang, H., Wang, S., Diao, N., Wang, F., Gao, Y., Chen, J., Shao, L., Weng, X., et al. Novel biomarkers distinguishing active tuberculosis from latent infection identified by gene expression profile of peripheral blood mononuclear cells. PLoS One, 6, 2011, e24290.
48. 48• Bloom, C.I., Graham, C.M., Berry, M.P., Wilkinson, K.A., Oni, T., Rozakeas, F., Xu, Z., Rossello-Urgell, J., Chaussabel, D., Banchereau, J., et al. Detectable changes in the blood transcriptome are present after two weeks of antituberculosis therapy. PLoS One, 7, 2012, e46191 This study expands on the previous longitudinal data, showing changes in the host response to TB as early as 2 weeks after therapy and demonstrates proof-of-principle that transcriptional profiles could be used for individual treatment monitoring.
49. 49 Horne, D.J., Royce, S.E., Gooze, L., Narita, M., Hopewell, P.C., Nahid, P., Steingart, K.R., Sputum monitoring during tuberculosis treatment for predicting outcome: systematic review and meta-analysis. Lancet Infect Dis 10 (2010), 387–394.
50. 50• Cliff, J.M., Lee, J.S., Constantinou, N., Cho, J.E., Clark, T.G., Ronacher, K., King, E.C., Lukey, P.T., Duncan, K., Van Helden, P.D., et al. Distinct phases of blood gene expression pattern through tuberculosis treatment reflect modulation of the humoral immune response. J Infect Dis 207 (2013), 18–29 This study shows that transcriptional responses to TB treatment can occur after only one week and characterizes these early responses as dominated by inflammatory responses reducing, whilst later changes show a restoration of B cell related transcripts.
51. 51 Maddocks, S., Scandurra, G.M., Nourse, C., Bye, C., Williams, R.B., Slobedman, B., Cunningham, A.L., Britton, W.J., Gene expression in HIV-1/Mycobacterium tuberculosis co-infected macrophages is dominated by M. tuberculosis. Tuberculosis (Edinb) 89 (2009), 285–293.
52. 52 Portevin, D., Gagneux, S., Comas, I., Young, D., Human macrophage responses to clinical isolates from the Mycobacterium tuberculosis complex discriminate between ancient and modern lineages. PLoS Pathog, 7, 2011, e1001307.
53. 53 de Jong, B.C., Hill, P.C., Aiken, A., Awine, T., Antonio, M., Adetifa, I.M., Jackson-Sillah, D.J., Fox, A., Deriemer, K., Gagneux, S., et al. Progression to active tuberculosis, but not transmission, varies by Mycobacterium tuberculosis lineage in The Gambia. J Infect Dis 198 (2008), 1037–1043.
54. 54 Caws, M., Thwaites, G., Dunstan, S., Hawn, T.R., Lan, N.T., Thuong, N.T., Stepniewska, K., Huyen, M.N., Bang, N.D., Loc, T.H., et al. The influence of host and bacterial genotype on the development of disseminated disease with Mycobacterium tuberculosis. PLoS Pathog, 4, 2008, e1000034.
55. 55 Thwaites, G., Caws, M., Chau, T.T., D'Sa, A., Lan, N.T., Huyen, M.N., Gagneux, S., Anh, P.T., Tho, D.Q., Torok, E., et al. Relationship between Mycobacterium tuberculosis genotype and the clinical phenotype of pulmonary and meningeal tuberculosis. J Clin Microbiol 46 (2008), 1363–1368.
56. 56 Fallahi-Sichani, M., El-Kebir, M., Marino, S., Kirschner, D.E., Linderman, J.J., Multiscale computational modeling reveals a critical role for TNF-alpha receptor 1 dynamics in tuberculosis granuloma formation. J Immunol 186 (2011), 3472–3483.
57. 57 Keane, J., Gershon, S., Wise, R.P., Mirabile-Levens, E., Kasznica, J., Schwieterman, W.D., Siegel, J.N., Braun, M.M., Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 345 (2001), 1098–1104.
58. 58 Bloom, C.I., Graham, C.M., Berry, M.P., Rozakeas, F., Redford, P.S., Wang, Y., Xu, Z., Wilkinson, K.A., Wilkinson, R.J., Kendrick, Y., et al. Transcriptional blood signatures distinguish pulmonary tuberculosis, pulmonary sarcoidosis, pneumonias and lung cancers. PLoS One, 5, 2013, e70630.